An immunohistochemistry (IHC) study on 50 SCLC samples revealed that 76% had DLL3 protein, with 54% showing moderate to high expression, suggesting that DLL3 could be an effective target for treatment. The gene discussed is DLL3; the disease is small cell lung carcinoma.